Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 513-526, August 2010

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes☆

  • Richard J. Riese, MD, PhD

      Affiliations

    • Pfizer Global Research and Development, New London, CT, USA
    • ,
  • Sriram Krishnaswami, PhD

      Affiliations

    • Pfizer Global Research and Development, New London, CT, USA
    • ,
  • Joel Kremer, MD

      Affiliations

    • Albany Medical College, Albany, NY, USA
    • Corresponding Author InformationCorresponding author. The Center for Rheumatology, 1367 Washington Ave., Albany, NY 12206, USA. Tel.: +1 518 489 4496; Fax: +1 518 533 1380.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Disclosures: Richard Riese and Sriram Krishnaswami are employees of Pfizer. The CP-690,550 studies reviewed in this article were sponsored by Pfizer Inc.

PII: S1521-6942(10)00027-6

doi:10.1016/j.berh.2010.02.003

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 513-526, August 2010

Article Tools

* Image Usage & Resolution